Recent share performance and business snapshot

Crinetics Pharmaceuticals (CRNX) has drawn investor attention after a weak month for the share price, with the stock showing negative returns over the past month and past 3 months despite a positive 1 year total return.

The clinical stage company focuses on rare endocrine diseases, with its lead candidate Paltusotine in Phase 3 trials and several earlier stage programs. This context may influence how investors weigh recent share price moves against longer term development prospects.

At the current share price of US$36.98, the recent 1 month share price return of 19.63% and 3 month share price return of 25.01% contrast with a 1 year total shareholder return of 4.46% and very large 3 and 5 year total shareholder returns. This indicates that momentum has faded recently, even though longer term holders still sit on sizeable gains.

If this kind of volatility has you thinking about where else growth stories might emerge in healthcare, you may want to scan our list of 34 healthcare AI stocks as a starting point for further research.

With Crinetics still loss making and its shares sitting well below the stated price target, the key question is whether the current valuation underestimates its pipeline or whether the market already reflects its future growth potential.

Most Popular Narrative: 55.1% Undervalued

The most followed narrative for Crinetics Pharmaceuticals puts fair value at about $82.43 per share versus the last close of $36.98, which is a wide gap that hinges on aggressive revenue growth and future profitability assumptions.

The shift in acromegaly care toward patient friendly oral therapies, combined with PALSONIFY’s positioning as a potential first medical treatment after surgery, can expand treated patient numbers across switch, naive, previously discontinued and lost to follow up groups, which would directly influence revenue growth.

Growing focus on chronic symptom control and quality of life in rare endocrine diseases, supported by PALSONIFY’s label that highlights both biochemical and symptom control, can support physician preference and patient driven demand, which may help sustain prescription volumes and future earnings.

Want to see what kind of revenue surge and margin shift this narrative is banking on, and what future earnings multiple ties it all together? The full story spells out a bold growth curve, a step change in profitability and a valuation multiple more often associated with fast growing sectors.

Result: Fair Value of $82.43 (UNDERVALUED)

However, that growth story could be knocked off course if PALSONIFY uptake lags expectations or if ongoing pipeline setbacks limit how many products ultimately reach the market.

Another angle on valuation

That $82.43 fair value from the narrative relies heavily on future earnings assumptions. Our DCF model tells a different story, assigning Crinetics a future cash flow value of $464.66 per share, which suggests that the shares may be deeply undervalued. This raises a key question: which set of assumptions seems more realistic to you?

Next Steps

If this mix of optimism and caution around Crinetics has you undecided, consider acting while the data is fresh. Weigh it against your own risk tolerance and goals, starting with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you do nothing with this insight, you risk missing other opportunities that fit your style, so keep building your watchlist while the market is presenting options.

• Spot potential mispricings early by scanning our 50 high quality undervalued stocks that combine solid fundamentals with market pessimism that could eventually unwind.
• Lock in more predictable income streams by reviewing 14 dividend fortresses that offer higher yields with a focus on resilience.
• Prioritize peace of mind by checking 67 resilient stocks with low risk scores designed for investors who want steadier profiles without stretching their risk budget.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.